Sera from persons with AIDS contain inhibitors of lymphocyte proliferation. Inhibitory activity can be detected before the development of AIDS in humans. There appear to be at least three distinct suppressive moieties, one of which is prostaglandin E 2 . We and others had previously shown that serum samples from subjects with AIDS contained antibody to the cell line HUT 102B2. We attempted to remove this antibody and to determine if that action would also remove the inhibitory activity present in human immunodeficiency virus-positive sera. We incubated sera from subjects with AIDS with HUT 102B2 cells and tested the resultant supernatants for inhibition of cell proliferation. We found that this procedure significantly reversed inhibition by serum. Other cells and cell lines were similarly tested, but only HUT 102B2 cells absorbed the inhibitory product(s). However, we determined that secretory material from another cell line, MLA 144, also reversed inhibition. The physical characteristics of the supernatant were investigated. Thus, two procedures and likely separate products, possibly cytokines, reverse immunosuppression by sera from persons with AIDS.
Sera from persons with AIDS contain inhibitors of lymphocyte proliferation (5, 6, 8, 10, 15) . Inhibitory activity can be detected before the development of AIDS in humans and is predictive of simian acquired immunodeficiency syndrome in monkeys (17, 18) . There appear to be at least three distinct suppressive moieties, one of which is prostaglandin E 2 (PGE 2 ) (9). We and others (7, 12) had previously shown that sera from subjects with AIDS contained antibody to the cell line HUT 102B2. We attempted to remove this antibody and to determine if that action would also remove the inhibitory activity present in human immunodeficiency virus type 1 (HIV-1)-positive sera.
MATERIALS AND METHODS
Patient serum samples. Experimental sera were obtained from patients in clinics at either the State University of New York Health Sciences Center in Syracuse or the University of Wisconsin Hospital and Clinics. Institutional Review Board review and authorization were obtained prior to initiation of the study, and appropriate informed consent was received from each participant. Serum samples were maintained as 1 to 2-ml aliquots at Ϫ70ЊC until used. We measured antibodies to HUT 102B2 cells and HIV-1 as previously described (12) .
Inhibition assay. Inhibition of lymphocyte proliferation by sera was determined as previously described (10) . Peripheral blood mononuclear cells, obtained from a healthy donor, were cultured with and without a suboptimal concentration of phytohemagglutinin (PHA) (Bacto Phytohemagglutinin-P; Difco Laboratories, Detroit, Mich.) in the presence of three different control serum samples and one or more patient serum samples. The suboptimal PHA concentration was experimentally determined by stimulating the cells from three controls with 1/25, 1/50, 1/75, 1/100, and 1/200 dilutions of mitogen. The maximal stimulation level was determined, and the first dilution giving net counts per minute below the maximal level was used in the inhibitory assays. After 96 h of culture at 37ЊC in 5% CO 2 , uptake of [ 3 H]thymidine over a 12-to 18-h labeling period was measured as counts per minute. For each serum sample tested, proliferation was calculated as a percentage of the mean level of thymidine incorporation by control cells cultured in serum samples from healthy donors. Sera supporting less than 75% proliferation were scored as inhibitory. This percentage was chosen on the basis of data demonstrating that the value for each control serum in an experiment deviated by no more than 15% from the mean value for the control group. Supernatants were added at the beginning of the incubation period unless otherwise noted, and control cultures were run concurrently with an equal volume of tissue culture medium substituting for test supernatants.
Cell lines and other cells. Cell lines were maintained in RPMI 1640 supplemented with antibiotics and 10% fetal calf serum (M. A. Bioproducts, Walkersville, Md.). GM-3638, GM-3639, and Molt-4 (GM-2219) cells were obtained from the National Institute of General Medical Sciences Human Genetic Mutant Cell Repository (Camden, N.J.); the H9 cell line was obtained from the National Institutes of Health (Bethesda, Md., courtesy of Larry Arthur); HUT 102B2 and MLA 144 cells were provided by Tom Waldman, National Institutes of Health; and CEM cells were obtained from the American Type Culture Collection (Rockville, Md.). The lines infected with HIV-1 were developed in our laboratories (20) and were shown to be infected by the presence of reverse transcriptase activity in all cases; infection was periodically confirmed by electron microscopy. All cell lines were greater than 90% viable as determined by eosin red dye exclusion. Human blood type 0 erythrocytes were obtained from the hospital blood bank.
Absorption of serum with cells. Cells to be used for absorption were first centrifuged over a Ficoll-Hypaque gradient to remove decaying cells. They were washed with Hanks balanced salt solution (Gibco, Grand Island, N.Y.) and adjusted to a preselected number of cells per milliliter, i.e., 50 ϫ 10 6 /ml, unless otherwise noted. The cells were centrifuged, test serum (usually 1 ml) was added, and the mixture was incubated for a predetermined time and temperature, i.e., 4ЊC for 30 min, unless noted differently. Following incubation, the mixture was spun and the supernatant serum was removed and assayed for its inhibitory activity (see above). Controls always included (i) concurrently treated sera from a Net proliferation either in counts per minute or expressed as a percentage of proliferation in serum of a healthy control (100%).
healthy donors and (ii) treated test sera without cells, with culture medium added to make up the volume. Untreated control and test sera were always assayed at the same time as the treated sera.
Calculations. Unless otherwise noted, the net counts per minute (PHA counts per minute minus background counts per minute) of cells cultured in the sera of healthy controls was considered 100% proliferation. In each experimental run, net counts per minute for other test sera were compared with this standard and expressed as percent proliferation.
RESULTS
Inhibitory activity is removed from HIV-1-positive sera by absorption with HUT 102B2 cells (Table 1 ). This effect was seen when the absorption was carried out at either 4 or 37ЊC (Fig. 1) . We often observed increased proliferation after absorption, i.e., the net counts per minute were higher than those observed for cells cultured in control sera. This finding was inconsistent even with sera from the same subject. As more absorbing cells and/or cycles were used, more inhibition was removed ( Fig. 1 and 2 ). Under the conditions described in Materials and Methods, absorption of sera with HUT 102B2 cells had little impact on the measurable titer of antibody to HUT 102B2 cells (or HIV-1). When sera were subjected to further absorptive cycles, the level of antibody to HUT 102B2 cells was reduced (data not shown). Peripheral blood mononuclear cells, sheep erythrocytes, human blood type O erythrocytes, and other cell lines did not remove inhibition. Just as HUT 102B2 cells removed inhibition, so did the same cell line coinfected with HIV-1 (Fig. 2) . The only other cell line which repeatedly reversed inhibition was MLA 144 ( Table 2) .
Reversal of suppression after contact with MLA 144 cells increased if the cell-serum mixtures were held longer and/or at 37ЊC. This result was sufficiently different from the results with HUT 102B2 cells to raise the question of whether secretion of active factors rather than absorption of an inhibitory moiety in serum takes place. Thus, supernatants from MLA 144 cells as well as from the cell lines shown in Fig. 2 were assayed for the ability to reverse inhibition by HIV-1-positive serum. Only that taken from MLA 144 cells was effective in reversing inhibition (Table 3) . MLA 144 supernatants commonly, but not always, also increased background counts.
We next determined the time in culture required for optimal production of an active supernatant. Replicate cultures of MLA 144 cells were placed in fresh media and held at 37ЊC in 5% CO 2 . Supernatants collected on days 1, 2, 3, and 4 were subsequently assayed for the ability to reverse inhibition of normal lymphocytes cultured in HIV-1-positive sera. Activity peaked on days 3 and 4. When the supernatants were serially diluted, the activity was reduced. Similarly treated supernatants from HUT 102B2 cells did not reverse inhibition.
As previously noted, absorbing HIV-1-positive sera with HUT 102B2 cells partially or totally reversed HIV-induced suppression. Adding MLA 144 supernatants to cultures containing HUT 102B2 cell-treated sera had no further effect on inhibition ( Table 4 ), suggesting that the effects operate through the same pathway.
We began to characterize the supernatants from MLA 144 cells by subjecting them to a variety of treatment protocols (Table 5) . Activity was not affected by three freeze-thaw cycles, by treatment with acid (pH 2.0) for 30 min, or by heating to   FIG. 1 . Results of two typical experiments are shown. In both experiments, serum from a subject with AIDS was assayed for inhibitory activity before and after absorption with HUT 102B2 cells. The level of proliferation in sera from healthy donors was considered 100%, and the test results were compared with that standard. In both experiments, patient serum was suppressive and inhibition was reversed by absorption with the cell line. In both experiments, the effects of temperature were assessed. In the second experiment, the effects of the numbers of absorbing cells were studied. ''Absorbed with 50 ϫ 10 6 ϫ 2'' indicates that sera underwent two successive absorptive cycles. See text for experimental details. 56ЊC for 30 min. However, heating to 56ЊC for 24 h, boiling for 15 min, or treatment with trypsin destroyed activity. The retentate within a filter, which had a cutoff value estimated by the manufacturer as a molecular weight of 30,000, partially restored activity, while the filtrate was ineffective.
DISCUSSION
We have shown that almost all patients with AIDS have inhibitors of lymphocyte proliferation in their sera (10, 18) . The detection of inhibitors is dependent on the conditions of study, specifically the relative concentrations of the cells, the serum, and the mitogen (10) . Inhibitory activity can be detected before the onset of clinical AIDS in humans and simian acquired immunodeficiency syndrome in nonhuman primates and can be predictive of these diseases. Its predictive value approached that of other markers, including CD4 lymphocyte counts (17, 18) . From this, we infer that the factors responsible for inhibition by serum might participate in the development of AIDS in HIV-1-infected individuals (16) .
We had studied the effects of inhibitory sera on a number of different cell lines (9) . To our surprise, we discerned four patterns of inhibition: inhibition of all cell lines, inhibition of one set of cell lines, inhibition of a reciprocal set of cell lines, and no inhibition (but some evidence of suppressed proliferation of peripheral blood mononuclear cells). We concluded from this investigation that there were at least three inhibitory factors in serum. We further determined that cyclo-oxygenase inhibitors, such as indomethacin, reversed suppression by some serum samples (9) . Suppression could be restored by exogenous PGE 2 . Cell lines known to have receptors to PGE 2 and shown to be inhibited by exogenous PGE 2 were also inhibited by some HIV-1-positive sera. Inhibition of these cells was reversed by indomethacin (9) . Thus, one of the inhibitors operated through PGE 2 . The other suppressor factors remain undefined.
In the present communication, we describe another approach to studying the inhibitory factors present in the sera of persons with AIDS. We considered the possibility that one of the suppressors might be an antibody against a cellular component. We had previously shown that sera from about 70% of AIDS subjects had antibodies to the cell line HUT 102B2, a T-cell lymphoma/leukemia line infected with the retrovirus human T-cell leukemia virus type 1 (12) . We reasoned that removal of this antibody might remove or at least lessen inhibition. In the present work, we report that absorption of sera from persons with AIDS reverses inhibition but that this seems unrelated to the presence of antibody to HUT 102B2 cells.
We questioned if the effect of HUT 102B2 cells was unique to that cell line. No other cell line or cell type reversed inhibition, with the exception of the simian cell line MLA 144. However, the conditions under which MLA 144 cells were most effective differed significantly from those optimal for absorption with HUT 102B2 cells. As we investigated the role of materials secreted by these cell lines, we determined that MLA 144 cells reversed inhibition by releasing something into the supernatant and not by absorption.
The HUT 102B2 and MLA 144 cell effects are not additive and may operate through the same pathway. We determined some physical characteristics of the MLA 144 supernatant (Table 5). The active moiety appears to be a Ͼ30,000-Da polypeptide which is not affected by acid treatment or repeated freezethaw cycles. Further studies are now in progress to identify it as well as the moiety removed by HUT 102B2 cells.
We had speculated that the inhibitory factors found in serum resulted from an ongoing contest between the virus and the immune response. Furthermore, we suggested that the inhibitors not only modulated immune responses but also retarded the replacement of host cells as they were destroyed in this interaction. Recent findings confirm that a vigorous cellular immune response is ongoing in HIV-1 infection (1, 11, 14, 19) . In addition, there are data, albeit sometimes conflicting, suggesting that the cytokine repertoire of infected hosts changes over time and may be related to the development of AIDS (2-4, 13).
The inhibitors in serum that we describe are likely either host-derived cytokines or virus products. Because of the timing of the appearance of inhibitors, i.e., not early in infection when the virus is at increased levels in the plasma, we believe that the action of cytokines is the more plausible explanation for inhibition. We suspect that the substances reversing inhibition described in this report will fall into the category of cytokines, i.e., an inhibitory cytokine removed by HUT 102B2 cells and a stimulatory cytokine released by MLA 144 cells. Identifying the AIDS-related inhibitors in serum will contribute to our understanding of the immunopathogenesis of HIV-1 infection and thus to the development of therapies aimed at maintaining the homeostasis manifested as clinical latency. 
